J. Gligorov Et Al. , "Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients," EUROPEAN JOURNAL OF CANCER , vol.82, pp.237-246, 2017
Gligorov, J. Et Al. 2017. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. EUROPEAN JOURNAL OF CANCER , vol.82 , 237-246.
Gligorov, J., Ataseven, B., Verrill, M., De laurentiis, M., Jung, K. H., Azim, H. A., ... Al-Sakaff, N.(2017). Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. EUROPEAN JOURNAL OF CANCER , vol.82, 237-246.
Gligorov, KAZIM Et Al. "Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients," EUROPEAN JOURNAL OF CANCER , vol.82, 237-246, 2017
Gligorov, KAZIM Et Al. "Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients." EUROPEAN JOURNAL OF CANCER , vol.82, pp.237-246, 2017
Gligorov, J. Et Al. (2017) . "Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients." EUROPEAN JOURNAL OF CANCER , vol.82, pp.237-246.
@article{article, author={KAZIM UYGUN Et Al. }, title={Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients}, journal={EUROPEAN JOURNAL OF CANCER}, year=2017, pages={237-246} }